Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Obesity Treatment

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Full results are slated for presentation at the American Diabetes Association meeting in June.

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite

Amgen Reports Year-Long Weight-Loss Maintenance With Monthly or Quarterly MariTide Dosing

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Eli Lilly Halts Diabetes Arm of Bimagrumab Obesity Trial Weeks After Launch

Novo Nordisk Launches Wegovy Weight-Loss Drug in India